{"id":"low-bup-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine is a semi-synthetic opioid that binds with high affinity but partial agonist activity at mu-opioid receptors. At low doses, it produces analgesic and anti-craving effects while maintaining a ceiling effect on respiratory depression, making it safer than full opioid agonists. This profile makes it suitable for pain management and opioid use disorder treatment with reduced overdose potential.","oneSentence":"Low-dose buprenorphine acts as a partial agonist at the mu-opioid receptor, providing analgesia and potentially reducing opioid cravings with lower overdose risk than full opioids.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:31.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"},{"name":"Chronic pain management"}]},"trialDetails":[{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT01690546","phase":"PHASE2","title":"Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence","status":"COMPLETED","sponsor":"Paolo Mannelli","startDate":"2012-09","conditions":"Opiate Dependence","enrollment":38},{"nctId":"NCT00000299","phase":"PHASE2","title":"Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-10","conditions":"Opioid-Related Disorders","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Subutex"],"phase":"phase_3","status":"active","brandName":"Low Bup Dose","genericName":"Low Bup Dose","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose buprenorphine acts as a partial agonist at the mu-opioid receptor, providing analgesia and potentially reducing opioid cravings with lower overdose risk than full opioids. Used for Opioid use disorder, Chronic pain management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}